Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The aim is to compare the available evidence on the efficacy and safety of deoxycholate and lipid amphotericin B formulations (AMBF) in the treatment of invasive fungal disease (IFD) in neonates. The review also aims to summarize current practices and recommendations. RECENT FINDINGS: To date most AMBF studies on neonates consist of retrospective reports and case series. The reviewed reports show that both amphotericin B deoxycholate (DAMB) and lipid formulations appear to have equal efficacy in treating IFD in neonates. The adverse effects of DAMB in neonates are considerably less than those in older children and adults. There is a trend of more nephrotoxicity reported with DAMB than with lipid formulations; however, the range reported is very wide (0-70%). Neonates with normal baseline renal function appeared to tolerate DAMB relatively well. A sodium intake of 4 mEq/kg/day may significantly reduce DAMB nephrotoxicity. SUMMARY: Deoxycholate amphotericin B is inexpensive and effective in treating neonatal IFD. It appears to be safe for use as first-line therapy if the underlying risk for nephrotoxicity is low and renal function and potassium are monitored closely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523
KOSSOFF, E. H., BUESCHER, E. S., & KARLOWICZ, M. G. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199806000-00014 · Cited by 330
Baley, J. E., Meyers, C., Kliegman, R. M., Jacobs, M. R., & Blumer, J. L. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)82674-5 · Cited by 184
Candidal Meningitis in Neonates: A 10-Year Review
Fernandez, M., Moylett, E. H., Noyola, D. E., & Baker, C. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313973 · Cited by 163
Liposomal amphotericin B treatment for neonatal fungal infections
SCARCELLA, A., PASQUARIELLO, M. B., GIUGLIANO, B., VENDEMMIA, M., & DE LUCIA, A. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199802000-00013 · Cited by 135
Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., & Janoff, A. S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.767 · Cited by 82
Cited by
Nanoparticles as drug delivery systems
Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70901-5 · Cited by 1,445
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
“Notably, amphotericin B is relatively well tolerated in neonates (258, 259).”
BackgroundMesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
Metadata
- Authors
- Turkova, A., Roilides, E., & Sharland, M.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2011-04
- Volume
- 24
- Issue
- 2
- Pages
- 163-171
- ISSN
- 0951-7375 (ISSN-L)
- OpenAlex
- W2005347833
- Cited by
- 45
- References
- 7
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice? https://app.cochat.ai/papers/10.1097/qco.0b013e328343614e
- The paper
- Turkova, A., Roilides, E., & Sharland, M. (2011). Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice? Current Opinion in Infectious Diseases. https://doi.org/10.1097/qco.0b013e328343614e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.